Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

All Conditions

Urinary Bladder Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Urinary Bladder Diseases

Urologic Diseases

Male Urogenital Diseases

Bladder cancer group represents patients attending or hospitalized in Urology department, Reims University Hospital and in whom, tumor is visualized during cystoscopy and confirmed by the histological examination of entire resected lesion after Trans Urethral Resection of Bladder Tumor (TURBT).

Control group includes patients consulting for cystoscopy examination in Urology department, Reims University Hospital without any tumor visualization during cystoscopy examination.

Urine vibrational analysis

Stéphane LARRE

This study aims to evaluate the performance of vibrational spectroscopy (Infrared and Raman spectroscopy techniques) in bladder cancer diagnosis using urine samples.

Urologic cancers affect the organs and structures of the male and female urinary tract and the male reproductive system. Bladder cancer (BCa) is the second urological cancer in incidence after prostate cancer and represents the 10th most common cancer in the world. This cancer has high recurrence and progression rates. Cystoscopy and urine cytology are the current gold-standard examination for bladder cancer. Nevertheless, the first is invasive and the latter has low sensitivity especially for low-grade bladder cancer. Therefore, it is critical to implement accurate, non- invasive and sensitive examination tool to diagnose patients with bladder cancer at an early stage.

On the one hand, urine is collected non-invasively and considered as a proximal biofluid from bladder. On the other hand, vibrational spectroscopy including Infrared and Raman spectroscopy is widely used for the analysis of biological samples and provides a molecular fingerprint of the sample with minimum or no sample preparation. Applied on urine, this technique may offer interesting alternative for bladder cancer diagnosis and monitoring. Hence, this research project aims to evaluate the analytical capabilities of urinary vibrational spectroscopy with the objective of developing a diagnostic test for urothelial bladder cancer.

The study is planned for 36 months. Patients that approve their participation in the study will respond to a questionnaire allowing us to have clinical information. From these patients, urine samples will be collected in Urology department of Reims University Hospital. Urine samples will be directly analyzed by Fourier Transform Infrared Spectroscopy and/or Surface-enhanced Raman spectroscopy then stored at -80°C for further analysis.

Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers

Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancer

Analyze urine samples by infrared spectroscopy after drying step and without any further sample preparation. The obtained spectra will be preprocessed and analyzed by multivariate algorithms to discriminate bladder cancer patients from control group.

Analyze urine samples by Surface-enhanced Raman spectroscopy after mixing urine samples with silver nanoparticles. The obtained spectra will be preprocessed and analyzed by multivariate algorithms to discriminate bladder cancer patients from control group.

CHU de Reims

Blood and Lymph Conditions

Hematologic Neoplasms

Hematologic Diseases

Patients on this study must have either a suspected or confirmed solid tumor or hematological cancer. The intervention performed in this study is the molecular analysis of cancer. The samples will be taken at the time of the patient's planned diagnostic or staging procedure. If the patient is scheduled for surgery a sample of tissue not required for their diagnosis will be obtained and used for this research study. If the patient has undergone a previous diagnostic procedure, some of the stored tissue from that procedure will be submitted for molecular analysis as well.

The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.

Molecular Analysis of Cancer

Andrew Schumacher, M.S.

Allison Jean, B.A.

Priscilla Merriam, M.D.

Howard Safran, M.D.

Maria Constantinou, M.D.

Anthony Mega, M.D.

Kimberly Perez, M.D.

Amy Pilotte, N. P.

Humera Khurshid, M.D.

Evgeny Yakirevich, M.D.

Murray Resnick, M.D.

James Butera, M.D.

Mary Anne Fenton, M.D.

Lucia Fontes-Bortes, N.P.

Peter Quesenberry, M.D.

Matthew Quesenberry, M.D.

John Reagan, M.D.

Eric Winer, M.D.

Thomas DiPetrillo, M.D.

Jaroslaw Hepel, M.D.

Kara Lynne Leonard, M.D.

David Tracey, P.A.

Inna Yakirevich, N.P.

Sharon Benson, N.P.

Heinrich Elinzano, M.D.

Timothy Kinsella, M.D.

Thomas Ng, M.D.

Maureen Jean, R.N.

Diane Martel, R.N.

Jennifer Collins, N.P.

Irene Kolberg, N.P.

Jodi Layton, M.D.

Fred Schiffman, M.D.

Edward Wittles, M.D.

Angela Taber, M.D.

Camille Higel-McGovern, N.P.

Amy Pilotte, N.P.

Xristin Maestri, N.P.

The purpose of this study is to discover genetic changes associated with different cancers. With the information from this study the investigators hope to provide better ways to prevent, detect and treat many cancers.

Many diseases can result from changes in a person's genetic material that causes cells to not work properly. Currently, researchers and doctors know some of the genetic changes that can cause disease, but they do not know all of the genetic changes that can cause disease.

This project is designed to identify genetic changes that can cause cancer in humans. Specimens will be collected from a scheduled diagnostic or routine (i.e. blood draw for counts) procedure and may include samples from the tissue itself (surgery), bone marrow, blood, saliva, urine, spinal fluid, sputum, joint fluid, seminal fluid, ascites (a fluid that fills up in the abdomen), and/or pleural fluid (fluid in the lung cavity), to either confirm the diagnosis of cancer or to help to decide how best to treat cancer or other illness. Additionally archived tissue may be analyzed. Samples may be stored for future use in later experiments. The Department of Pathology at Rhode Island Hospital will store the samples.

Information from the medical record, such as responses to treatments or family history of cancer, will be collected.

Complex, progressive, multigenic, somatic mutations of the genome are now widely accepted as the primary driving force in the evolution of cancer initiation, growth, metastasis and pharmacoresistance. Different types of tumors are associated with mutations in distinct sets of genes, and there is a pressing need for a sequencing-based method of analyzing panels of candidate genes that differ for each tumor type.

Traditional approaches to sequence analysis employing capillary electrophoresis-based Sanger sequencing are widely used to guide therapy for patients with lung and colorectal cancer and for melanoma, sarcomas, leukemias and lymphomas. This technology is limited in throughput, scalability, speed, and resolution. The emerging technology such as next-generation sequencing (NGS) - holds a number of advantages over traditional methods, including the ability to fully sequence large numbers of genes in a single test and simultaneously detect deletions, insertions, copy number alterations, translocations, and exome-wide base substitutions in all known cancer-related genes.

Sequencing the whole genome is financially prohibitive for many potentially valuable applications. One alternative to whole genome methods is target enrichment, such as exome sequencing, which captures and sequences only protein coding regions. The exome represents 1-2% of the human genome; however contains the vast majority of disease causing alterations. In addition to exome sequencing, full-length transcriptome (mRNA) sequencing offers a fast and inexpensive alternative. It is an easier method to identify coding sequences and capture variants in genes that are expressed, as well as to generate additional information, such as gene expression level and splicing patterns.

The goal of this study is to investigate genomic, transcriptomic and proteomic alterations in human solid cancers and hematologic malignancies.

Patients \>18 y.o. diagnosed with cancer (including any solid tumor or hematologic malignancy) or patients who are undergoing a procedure for the diagnosis of a presumed cancer are eligible.

The research analysis will be performed by the department of pathology or the division of hematology oncology. The body/blood tissue analyzed will be from extra tissue/blood that is not needed for diagnosis or evaluation of the patient's cancer. All samples will be de-identified. Samples will be stored for an indefinite period of time or until all samples are utilized.

Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis

MOLECULAR TESTING OF CANCER BY INTEGRATED GENOMIC, TRANSCRIPTOMIC, AND PROTEOMIC ANALYSIS

Rhode Island Hospital

Digestive System Diseases

Adenocarcinoma

Crohn Disease

Intestinal Diseases

Inflammatory Bowel Diseases

Gastroenteritis

Gastrointestinal Diseases

Herbal and Botanical

All Drugs and Chemicals

Cola

We will use colonic biopsies performed in the gastroenterology after obtaining consent from the patient and the agreement of the committee for the protection of persons. 5 biopsy will be performed for all patients except those with colon cancer for xhich we realize only 3 colonic biopsy (1 in healthy area and 2 in cancerous area )

To obtain statistically significant results we will establish the following six study groups, as far as possible matched for age and sex:

* healthy patients;
* patients with colonic Crohn disease in acute phase;
* patients with colonic Crohn disease in chronic phase;
* patients with ulcerative colitis in acute phase;
* patients with ulcerative colitis in chronic phase;
* patients with colon cancer

An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.

We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.

Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating).

Analysis

HEBUTERNE Xavier, PhD

The inflammatory tumor micro-environment is a consequence and a driver of tumorogenesis. On one hand it promotes antitumor immune responses and on the other hand it favors development and progression of cancerous lesions.

Factors regulating the complex interplay between epithelial and immune cells are still poorly characterized. Extracellular ATP (eATP) acting on the purinergic P2X7 receptors (P2RX7) has recently emerged as a key signaling pathway in the immune response.

Recent data have revealed the crucial role of P2RX7-NLRP3-Caspase-1 for priming dendritic cells (DC) within the tumor microenvironment upon treatment with certain types of chemotherapy drugs. Despite this important discovery, no previous study has so far investigated the global in vivo effect of P2RX7 modulation in inflammation-induced carcinogenesis of mucosal tissues.

Our consortium, endowed by a long standing experience in the field of mucosal immunology, inflammation and signaling, already demonstrated that the P2RX7 is differentially expressed in the mucosa of patients with active and quiescent inflammatory bowel disease (IBD), where eATP is present at very high concentration, and that P2RX7 controls an amplification loop of the inflammatory response (Cesaro et al., 2010). Furthermore, we uncovered that P2RX7 controls homeostasis, survival and function of regulatory T cells (Hubert et al., 2010). In addition, our recent demonstration that P2RX7 deficiency lowered mucosal inflammation but unexpectedly enhanced tumor formation in vivo warrants additional efforts to explore the molecular and cellular mechanisms accounting for this effect and suggest that enhancing P2RX7 function may have an anti-tumor therapeutic effect.

These observations emphasize the tumor suppressor role of P2X7 receptor, warrant further investigation to better understand the molecular mechanisms responsible for this anti-tumor effect and suggest that enhancing the function of P2X7R could have a therapeutic effect significant antitumor.

Our main objectives is to explore the role of P2RX7 in healthy, inflammatory and cancerous colonic mucosa. For this we will map the expression of the protein P2RX7 and realize genotype of P2RX7 forms in inflammatory diseases and cancer of the colon.

Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa

The evaluation of the level of expression of P2RX7 will realized by tissue microarray (TMA). TMA is produced using colonic biopsies fixed in 10% formalin. Plug of paraffin embedded tissue will be selected from stained with hematoxylin eosin saffron corresponding cuts. This selection of the tissue area taken from the donor block must be done carefully, conditioning the quality of the "array". In practice, for each patient, 3 Plug of 0.6 mm shall be taken from a biopsy performed in pathological tissue. A total of 156 spots TMA of 0.6 mm diameter plug shall be included according to a pre-established in a receiver block plane (consisting of virgin paraffin).

Five isoforms of the P2RX7 protein are described and each of its isoforms have many single nucleotide polymorphisms (SNPs). Among the 1754 mutations identified, 33 have been referenced in Pubmed publications and 4 are associated with diseases such as osteoarthritis, chronic pain and leukemias. Thus, the function of P2X7R may be affected by the expression of variants "gain of function" or "loss of function" and it is important to map the expression of these variants to anderstand the role of P2X7R in inflammatory bowel diseases and colonic cancer.

Genotyping will be conducted on colonic biopsy and on blood samples (to demonstrate the feasibility of this technique much less debilitating). We will use the platform MassARRAY SNP multiplex (present in my home lab) by following the procedures established by the platform.

Centre Hospitalier Universitaire de Nice

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers	NCT06087016	Urinary Bladder...	Urine vibration...	18 Years -	CHU de Reims
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis	NCT02213822	Solid Tumors Hematological M...	Molecular Analy...	18 Years -	Rhode Island Hospital
Urinary Markers by SpectrosCopy: Diagnostic Aid in oncologY - Application to Urological Cancers	NCT06087016	Urinary Bladder...	Urine vibration...	18 Years -	CHU de Reims
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis	NCT02213822	Solid Tumors Hematological M...	Molecular Analy...	18 Years -	Rhode Island Hospital
Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant Colonic Mucosa	NCT02293811	Crohn Disease-A...	Analysis	18 Years -	Centre Hospitalier Universitaire de Nice
Molecular Testing of Cancer by Integrated Genomic, Transcriptomic, and Proteomic Analysis	NCT02213822	Solid Tumors Hematological M...	Molecular Analy...	18 Years -	Rhode Island Hospital

Spots Global Cancer Trial Database for analysis

Every month we try and update this database with for analysis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for analysis

Every month we try and update this database with for analysis cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for analysis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.